Zimmer Holdings and ISTO Technologies announced a Phase III clinical study to evaluate DeNovo ET Engineered Tissue Graft, an engineered cartilage implant intended to repair cartilage defects in the knee. DeNovo ET Graft is being developed under a collaborative relationship between ISTO and Zimmer.
Asian shares and the euro eased on Tuesday, with a relief rally from last week's heavy selling faltering quickly …
There are no comments yet